Cargando…
Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice
BACKGROUND: The receptor tyrosine kinase family includes many transmembrane proteins with diverse physiological and pathophysiological functions. The involvement of tyrosine kinase signaling in promoting a more aggressive tumor phenotype within the context of chemotherapeutic evasion is gaining reco...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286430/ https://www.ncbi.nlm.nih.gov/pubmed/22226043 http://dx.doi.org/10.1186/1476-4598-11-2 |
_version_ | 1782224556573851648 |
---|---|
author | Marshall, Aaron M McClaine, Rebecca J Gurusamy, Devikala Gray, Jerilyn K Lewnard, Kara E Khan, Sohaib A Waltz, Susan E |
author_facet | Marshall, Aaron M McClaine, Rebecca J Gurusamy, Devikala Gray, Jerilyn K Lewnard, Kara E Khan, Sohaib A Waltz, Susan E |
author_sort | Marshall, Aaron M |
collection | PubMed |
description | BACKGROUND: The receptor tyrosine kinase family includes many transmembrane proteins with diverse physiological and pathophysiological functions. The involvement of tyrosine kinase signaling in promoting a more aggressive tumor phenotype within the context of chemotherapeutic evasion is gaining recognition. The Ron receptor is a tyrosine kinase receptor that has been implicated in the progression of breast cancer and evasion of tamoxifen therapy. RESULTS: Here, we report that Ron expression is correlated with in situ, estrogen receptor alpha (ERα)-positive tumors, and is higher in breast tumors following neoadjuvant tamoxifen therapy. We also demonstrate that the majority of mammary tumors isolated from transgenic mice with mammary specific-Ron overexpression (MMTV-Ron mice), exhibit appreciable ER expression. Moreover, genetic-ablation of ERα, in the context of Ron overexpression, leads to delayed mammary tumor initiation and growth, but also results in an increased metastasis. CONCLUSIONS: Ron receptor overexpression is associated with ERα-positive human and murine breast tumors. In addition, loss of ERα on a Ron overexpressing background in mice leads to the development of breast tumors which grow slower but which exhibit more metastasis and suggests that targeting of ERα, as in the case of tamoxifen therapy, may reduce the growth of Ron overexpressing breast cancers but may cause these tumors to be more metastatic. |
format | Online Article Text |
id | pubmed-3286430 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32864302012-02-25 Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice Marshall, Aaron M McClaine, Rebecca J Gurusamy, Devikala Gray, Jerilyn K Lewnard, Kara E Khan, Sohaib A Waltz, Susan E Mol Cancer Research BACKGROUND: The receptor tyrosine kinase family includes many transmembrane proteins with diverse physiological and pathophysiological functions. The involvement of tyrosine kinase signaling in promoting a more aggressive tumor phenotype within the context of chemotherapeutic evasion is gaining recognition. The Ron receptor is a tyrosine kinase receptor that has been implicated in the progression of breast cancer and evasion of tamoxifen therapy. RESULTS: Here, we report that Ron expression is correlated with in situ, estrogen receptor alpha (ERα)-positive tumors, and is higher in breast tumors following neoadjuvant tamoxifen therapy. We also demonstrate that the majority of mammary tumors isolated from transgenic mice with mammary specific-Ron overexpression (MMTV-Ron mice), exhibit appreciable ER expression. Moreover, genetic-ablation of ERα, in the context of Ron overexpression, leads to delayed mammary tumor initiation and growth, but also results in an increased metastasis. CONCLUSIONS: Ron receptor overexpression is associated with ERα-positive human and murine breast tumors. In addition, loss of ERα on a Ron overexpressing background in mice leads to the development of breast tumors which grow slower but which exhibit more metastasis and suggests that targeting of ERα, as in the case of tamoxifen therapy, may reduce the growth of Ron overexpressing breast cancers but may cause these tumors to be more metastatic. BioMed Central 2012-01-06 /pmc/articles/PMC3286430/ /pubmed/22226043 http://dx.doi.org/10.1186/1476-4598-11-2 Text en Copyright ©2012 Marshall et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Marshall, Aaron M McClaine, Rebecca J Gurusamy, Devikala Gray, Jerilyn K Lewnard, Kara E Khan, Sohaib A Waltz, Susan E Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice |
title | Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice |
title_full | Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice |
title_fullStr | Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice |
title_full_unstemmed | Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice |
title_short | Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice |
title_sort | estrogen receptor alpha deletion enhances the metastatic phenotype of ron overexpressing mammary tumors in mice |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286430/ https://www.ncbi.nlm.nih.gov/pubmed/22226043 http://dx.doi.org/10.1186/1476-4598-11-2 |
work_keys_str_mv | AT marshallaaronm estrogenreceptoralphadeletionenhancesthemetastaticphenotypeofronoverexpressingmammarytumorsinmice AT mcclainerebeccaj estrogenreceptoralphadeletionenhancesthemetastaticphenotypeofronoverexpressingmammarytumorsinmice AT gurusamydevikala estrogenreceptoralphadeletionenhancesthemetastaticphenotypeofronoverexpressingmammarytumorsinmice AT grayjerilynk estrogenreceptoralphadeletionenhancesthemetastaticphenotypeofronoverexpressingmammarytumorsinmice AT lewnardkarae estrogenreceptoralphadeletionenhancesthemetastaticphenotypeofronoverexpressingmammarytumorsinmice AT khansohaiba estrogenreceptoralphadeletionenhancesthemetastaticphenotypeofronoverexpressingmammarytumorsinmice AT waltzsusane estrogenreceptoralphadeletionenhancesthemetastaticphenotypeofronoverexpressingmammarytumorsinmice |